drugset
drugset / Trial / NCT04958187

Study to Evaluate the Pharmacokinetics of ANG-3777 in Hemodialysis Subjects

NCT04958187 ↗

Phase 1 Unknown 16 enrolled Angion Biomedica Corp Nucleus Network Ltd · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics and safety of a single-dose of ANG-3777 in subjects with renal failure receiving maintenance hemodialysis.

Timeline

Start
2021-07
Primary completion
2021-10
Completion
2021-10

Drugs

EvaluationDrugModalityDoseRoute
Subject TEREVALEFIM Small molecule 2 mg/kg Intravenous

Indications

No indication recorded.